In the last trading session, 2.09 million Capricor Therapeutics Inc (NASDAQ:CAPR) shares changed hands as the company’s beta touched 0.60. With the company’s per share price at $6.88 changed hands at -$0.28 or -3.91% during last session, the market valuation stood at $314.47M. CAPR’s last price was a discount, traded about -240.12% off its 52-week high of $23.40. The share price had its 52-week low at $3.52, which suggests the last value was 48.84% up since then. When we look at Capricor Therapeutics Inc’s average trading volume, we note the 10-day average is 3.77 million shares, with the 3-month average coming to 3.03 million.
Analysts gave the Capricor Therapeutics Inc (CAPR) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.00. If we narrow down to specifics, the data shows that 0 out of 3 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended CAPR as a Hold, 3 felt it is a Buy and 0 rated the stock as Underweight. Capricor Therapeutics Inc’s EPS for the current quarter is expected to be -0.46.
Capricor Therapeutics Inc (NASDAQ:CAPR) trade information
Instantly CAPR was in red as seen at the end of in last trading. With action -9.95%, the performance over the past five days has been red. The company’s shares are showing year-to-date upside of 42.15%, with the 5-day performance at -9.95% in the red. However, in the 30-day time frame, Capricor Therapeutics Inc (NASDAQ:CAPR) is -43.56% down. Looking at the short shares, we see there were 10.21 million shares sold at short interest cover period of 4.04 days.
The consensus price target for the stock as assigned by Wall Street analysts is 22, meaning bulls need an upside of 68.73% from its current market value. According to analyst projections, CAPR’s forecast low is 20 with 24 as the target high. To hit the forecast high, the stock’s price needs a -248.84% plunge from its current level, while the stock would need to soar -190.7% for it to hit the projected low.
Capricor Therapeutics Inc (CAPR) estimates and forecasts
Year-over-year growth is forecast to reach 350.10% up from the last financial year.
Consensus estimates given by 10 financial analysts project the company’s revenue in the current quarter to hit an average of 1.28M. 10 analysts are of the opinion that Capricor Therapeutics Inc’s revenue for the current quarter will be 30.38M. The company’s revenue for the corresponding quarters a year ago was 3.97M and 2.26M respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at -67.82%. The estimates for the next quarter sales put growth at 1,243.27%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 11.01%. The 2025 estimates are for Capricor Therapeutics Inc earnings to decrease by -66.26%, but the outlook for the next 5-year period is at 85.74% per year.
CAPR Dividends
Capricor Therapeutics Inc is expected to release its next quarterly earnings report on 2025-May-13.
Capricor Therapeutics Inc (NASDAQ:CAPR)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 16.80% of Capricor Therapeutics Inc shares while 40.97% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 49.24%. There are 40.97% institutions holding the Capricor Therapeutics Inc stock share, with BLACKROCK INC. the top institutional holder. As of 2024-06-30, the company held 5.1145% of the shares, roughly 1.63 million CAPR shares worth $7.77 million.
VANGUARD GROUP INC holds the second largest percentage of outstanding shares, with 4.8645% or 1.55 million shares worth $7.39 million as of 2024-06-30.
Among Mutual Funds, the top two as of Mar 31, 2025 were VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and SPDR SERIES TRUST-SPDR(R) S&P(R) Biotech ETF . With 1.19 shares estimated at $8.19 million under it, the former controlled 2.61% of total outstanding shares. On the other hand, SPDR SERIES TRUST-SPDR(R) S&P(R) Biotech ETF held about 2.09% of the shares, roughly 954.91 shares worth around $6.57 million.
